Confidential settlements in securities-fraud stemming from Valeant’s governance and disclosure failures
Plaintiff(s):
Multiple institutional investors
Case type / claims:
Governance-related securities fraud arising from undisclosed relationships with specialty pharmacies, an unsustainable price-gouging model, and later financial restatements and regulatory investigations
Defendant(s):
Valeant Pharmaceuticals International, Inc.
Jurisdiction:
U.S. District Court for the District of New Jersey
Year:
2025
Outcome:
- Confidential opt-out settlements for institutional clients.
- Held Valeant accountable for governance failures tied to undisclosed pharmacy arrangements and misleading financial reporting.
